How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? (Q51099296)

29 March 2018

editorial

0 references

title

How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? (English)

1 reference

29 March 2018

1 reference

2

1 reference

29 March 2018

Marc Peeters

series ordinal

3

1 reference

29 March 2018

author name string

Giuseppe Bronte

series ordinal

1

1 reference

29 March 2018

Antonio Russo

series ordinal

4

1 reference

29 March 2018

language of work or name

English

0 references

publication date

27 March 2014

1 reference

29 March 2018

Expert Opinion on Biological Therapy

published in

1 reference

29 March 2018

volume

14

1 reference

29 March 2018

issue

6

1 reference

29 March 2018

page(s)

743-748

1 reference

29 March 2018

The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review.

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.902926

10.1517/14712598.2014.902926

21 January 2018

Identifiers

DOI

1 reference

29 March 2018

release_epoz7lhiwzbnzati4dsitcpwmi

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/epoz7lhiwzbnzati4dsitcpwmi

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

24673103

1 reference

29 March 2018